4/A: BridgeBio Pharma Director Amends Filing to Correct Share Holdings

A BridgeBio Pharma director, Frank McCormick, amended a previous filing to correct the reported number of shares held, reflecting a gift of 7,400 shares.

Summary

• Frank McCormick, a director at BridgeBio Pharma, filed an amended Form 4 to correct the number of shares he beneficially owns.
• The amendment was filed on January 8, 2025, and corrects a previous filing from December 27, 2024.
• The corrected filing shows that on December 26, 2024, Mr. McCormick gifted 7,400 shares of BridgeBio Pharma common stock.
• Following the transaction, Mr. McCormick directly owns 112,686 shares and indirectly owns 979,979 shares through the Francis P. McCormick Rev Trust U/A DTD 1/27/2017.

Sentiment

Score: 7

Explanation: The document is a routine correction of a filing, and the transaction itself is a gift of shares, which is neither positive nor negative for the company's performance. The sentiment is neutral to slightly positive due to the correction of the filing.

Industry Context

This is a routine filing related to changes in beneficial ownership by a company director, which is common in the biotech industry.

Comparison to Industry Standards

• These types of filings are standard practice for directors and officers of publicly traded companies, such as BridgeBio Pharma, and are comparable to similar filings from other biotech companies like Amgen or Gilead.
• The reporting of share transactions and beneficial ownership is a common requirement for all publicly listed companies.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders regarding the ownership of company stock by its directors.

Key Dates

Keywords

BridgeBio Pharma, Frank McCormick, share holdings, beneficial ownership, Form 4, SEC filing, director, stock gift